Beyond GLP1s: The race for nextgen obesity drugs starts in the preclinical models
BioSpace
Efficacy plateaus, muscle loss and weight rebound are testing the limits of GLP-1 success, pushing companies toward new mechanisms and multitarget designs to close the gap.
pharminent
September 2, 2026 (Last updated: September 7, 2026)
BioSpace
Efficacy plateaus, muscle loss and weight rebound are testing the limits of GLP-1 success, pushing companies toward new mechanisms and multitarget designs to close the gap.